Clinical Scorecard: Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

At a Glance

Key Highlights

• iPSC models shift drug discovery towards human biology, enabling earlier validation of therapeutic hypotheses.
• They preserve patient-specific genetics and allow differentiation into disease-relevant cell types.
• Standardized platforms enhance consistency and comparability of iPSC-derived data.
• iPSC models can systematically identify disease subtypes and support precision medicine strategies.
• Project Mosaic exemplifies the use of patient-specific iPSC models in addressing ALS heterogeneity.

Guideline-Based Recommendations

Diagnosis

• Utilize iPSC-derived models to study disease phenotypes in a human-relevant context.

Management

• Incorporate iPSC models in early discovery to inform development decisions for rare diseases.

Monitoring & Follow-up

• Ensure genetic stability, differentiation fidelity, and functional maturity in iPSC models.

Risks

• Avoid reliance on a single model system; integrate iPSCs with primary cells and other models as needed.

Patient & Prescribing Data

Individuals with rare diseases, particularly those with sporadic forms of conditions like ALS.

iPSC models can enhance understanding of disease mechanisms and improve matching of therapies to patient subtypes.

Clinical Best Practices

• Define clear phenotypes and research questions when developing disease-specific iPSC models.
• Focus on scalability and continuity in data generation across different model systems.
• Combine iPSC models with other approaches to validate findings and address specific functional questions.

References

• iXCells Biotechnologies